How many drugs treat Atrophic vaginitis?

Drug Landscape tracks 10 marketed treatments for Atrophic vaginitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Atrophic vaginitis?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/atrophic-vaginitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Atrophic vaginitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atrophic vaginitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Atrophic vaginitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Slynd	DROSPIRENONE	Exeltis Usa Inc	Progestin	Mineralocorticoid receptor	2019-01-01
Femring	ESTRADIOL ACETATE	Apil	Estrogen	estrogen receptors	2003-01-01
Ogen .625	estrone sulphate	Pfizer	estropipate	Steryl-sulfatase	1977-01-01
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01
Micronor	norethisterone	Johnson & Johnson	Progestin	GnRH receptors	1962-01-01
Synestrol	DIENESTROL	Johnson & Johnson	dienestrol	Estrogen receptor	1947-01-01
Ortho-Novum 10/11-21	Ethinylestradiol	Merck & Co.	Estrogen	Estrogen receptor	1943-01-01
Progesteron	Progesteron	Minia University		Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
Endometrin	progesterone	Ferring	Progesterone [EPC]	Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
Depo-Provera	medroxyprogesterone	Pfizer	Progestin	Progesterone receptor	1959-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Atrophic vaginitis:

Cite this brief

Drug Landscape (2026). Atrophic vaginitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/atrophic-vaginitis. Accessed 2026-06-10.

Atrophic vaginitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing